

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Oventus Medical Limited
ABN	12 608 393 282

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Melvyn John Bridges
Date of last notice	2 July 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Interests held by: Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust Parma Corporation Pty Ltd Lucille Bridges (spouse) Adinbri Super Pty Ltd atf The Bridges Super Fund
Date of change	16 September 2021 to 22 September 2021

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p>Direct: 75,367 Ordinary Shares; & 50,000 Options at \$0.4228 ea, expiring 8 December 2024</p> <p>Indirect – interests held by Parma Corporation Pty Ltd 1,587,595 Ordinary Shares</p> <p>Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 474,276 Ordinary Shares & 300,000 Options at \$0.40 ea, expiring 7 August 2025</p> <p>Indirect – interests held by Adinbri Super Pty Ltd as trustee for the Bridges Super Fund 987,609 Ordinary Shares & 83,335 Options exercisable at \$0.24 ea, expiring 29 June 2023</p> <p>Indirect – Lucille Bridges (spouse) 158,203 Ordinary Shares</p>
Class	Ordinary Shares
Number acquired	<p>1,300,000 Ordinary Shares Indirect:</p> <p>Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 400,000 Ordinary Shares</p> <p>Adinbri Super Pty Ltd as trustee for the Bridges Super Fund 700,000 Ordinary Shares</p> <p>Lucille Bridges (spouse) 200,000 Ordinary Shares</p>
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$144,772.23

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<p>Direct: 75,367 Ordinary Shares; & 50,000 Options at \$0.4228 ea, expiring 8 December 2024</p> <p>Indirect – interests held by Parma Corporation Pty Ltd 1,587,595 Ordinary Shares</p> <p>Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 874,276 Ordinary Shares & 300,000 Options at \$0.40 ea, expiring 7 August 2025</p> <p>Indirect – interests held by Adinbri Super Pty Ltd as trustee for the Bridges Super Fund 1,687,609 Ordinary Shares & 83,335 Options exercisable at \$0.24 ea, expiring 29 June 2023</p> <p>Indirect – Lucille Bridges (spouse) 358,203 Ordinary Shares</p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Purchased on market

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest after change	
-----------------------	--

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	Not in a Closed Period
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.